New combo attack on prostate cancer liver spread begins safety trial
NCT ID NCT07145177
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have already tried at least one hormone therapy. The main goal is to track side effects and see if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If this combination proves safe, it could offer a new treatment option for men with prostate cancer that has spread to the liver and stopped responding to hormone therapy.
What could go wrong
This is a very early (phase 1b) and small study (30 people) focused on safety, not effectiveness. The added liver treatments may increase side effects, and the approach may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact